700804-16-6Relevant academic research and scientific papers
PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF
-
Paragraph 0225-0226; 0231, (2020/11/23)
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 0346-0348, (2019/04/25)
Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
-
Page/Page column 234; 235, (2015/07/07)
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Paragraph 1310; 1311, (2015/06/17)
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other
TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES
-
Page/Page column 88, (2008/12/06)
Novel triazolopyridine compounds are disclosed that have a formula represented by Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, ECM degradation, joint degradation and/or inflammation, and others.
